Genetic Information Assistant in Telegenetics

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is: • Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing? Participants will: - have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot - answer questions about their cancer genetic knowledge and how they are doing - provide a saliva sample for genetic testing to test for cancer gene mutations - have their genetic testing results provided to them. - have the option to share their genetic testing results with family members Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.

Clinical Trial Description

High risk patients will be randomized to standard of care telegenetics with a UVA Genetic Counselor (GC) for pre-test counseling or to the novel interventional arm of pre-test counseling via Genetic Information Assistant (GIA). Participants in the study will receive their link for a telegenetics appointment or GIA link based on randomization and patients will complete pre-test genetic counseling via their assigned treatment arm. Participants will not be masked to their trial arm assignment. In the telegenetics arm, patients will be offered a video visit scheduled through Epic zoom or a phone visit in our cancer genetics clinic per standard of care. Patients randomized to the GIA arm will receive a personalized link based on their family history. At the completion of counseling, participants will be offered genetic testing. If they agree, they will be mailed a saliva kit via Invitae Genetics for panel based genetic testing via The Invitae Common Hereditary Cancers panel to analyze 47 genes associated with cancers of the breast, ovary, uterus, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas. ;

Study Design

Related Conditions & MeSH terms

Gene Mutation-Related Cancer
Genetic Predisposition
Genetic Predisposition to Disease

Clinical Trial Details

NCT number	NCT06089421
Study type	Interventional
Source	University of Virginia
Contact	Graham Fowler
Phone	(434) 323-1749
Email	NVG4WM@uvahealth.org
Status	Not yet recruiting
Phase	N/A
Start date	October 20, 2023
Completion date	March 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04746794` - Early Detection of GEnetic Risk (EDGE)	N/A
Completed	`NCT03792685` - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention	N/A
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Terminated	`NCT04119596` - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting	`NCT04141462` - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer	N/A
Completed	`NCT02826330` - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting	`NCT05929976` - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting	`NCT04620278` - Genetic Investigation of Cancer Predisposition
Active, not recruiting	`NCT02373709` - Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
Completed	`NCT05975489` - Genetics in the Effect of Caffeine on Fat Oxidation	N/A
Completed	`NCT03954652` - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"	N/A
Completed	`NCT04113239` - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation	`NCT04373525` - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed	`NCT03362099` - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	Phase 4
Recruiting	`NCT05857670` - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting	`NCT04774445` - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes	N/A
Not yet recruiting	`NCT06377033` - Using the EHR to Advance Genomic Medicine Across a Diverse Health System	N/A
Recruiting	`NCT05759143` - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing	N/A
Active, not recruiting	`NCT04920513` - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Active, not recruiting	`NCT04781205` - Genome Driven Primary Care Clinics - an RCT	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.